  Zika<pathogen> virus<pathogen> ( ZIKV) recently emerged as a global public health emergency of international concern. ZIKV is responsible for severe neurological complications in adults and infection during pregnancy and can lead to congenital Zika syndrome<disease>. There is no licensed vaccine or drug to prevent or treat ZIKV infection. Areas covered: The aim of this article is to provide an overview and update of the progress of research on anti-ZIKV vaccine and medications until the end of 2017 , with a special emphasis on drugs that can be used during pregnancy. Expert commentary: Development of new vaccines and drugs is challenging and several points particular to ZIKV infections augment this difficulty: ( 1) Cross-reactions between ZIKV and other flaviviruses , the impact of ZIKV vaccination on subsequent flavivirus<pathogen> infections , and vice-versa , is unknown , ( 2) Drugs against ZIKV should be safe in pregnant women , and ( 3) Evaluation of the efficacy of vaccine and drugs against ZIKV in clinical trials phase II-IV will be complicated due to the decline of ZIKV circulation.